Zepbound, Mounjaro, and Ozempic: A Bariatric Surgeon's Honest Comparison

Zepbound, Mounjaro, and Ozempic are the three most talked-about weight loss medications right now, and for good reason. They represent a genuine shift in how we treat obesity. Ozempic contains semaglutide and works on GLP-1 receptors. Mounjaro and Zepbound both contain tirzepatide and work on GLP-1 and GIP receptors. In clinical trials, tirzepatide-based medications have shown slightly more weight loss than semaglutide, but all three can produce meaningful results when used correctly. As a bariatric surgeon who has performed over 4,000 weight loss surgeries in the past two decades, I want to give you a straightforward comparison so you can have an informed conversation with your doctor.

How Do These Medications Actually Work?

All three of these medications belong to a class called GLP-1 medications, though Mounjaro and Zepbound are technically “dual agonists” because they target two hormone receptors instead of one.

Here is the basic breakdown:

• Ozempic (semaglutide): Mimics GLP-1, a hormone your gut releases after eating. GLP-1 slows stomach emptying, reduces appetite, and helps regulate blood sugar. Ozempic is FDA-approved for type 2 diabetes, though it is widely prescribed off-label for weight loss. Its sister drug Wegovy contains the same active ingredient at a higher dose and is approved specifically for weight management.

• Mounjaro (tirzepatide): Mimics both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual action appears to produce stronger effects on appetite, blood sugar control, and weight loss. Mounjaro is FDA-approved for type 2 diabetes.

• Zepbound (tirzepatide): Contains the exact same molecule as Mounjaro. The only difference is the FDA approval. Zepbound is approved specifically for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition.

So Mounjaro and Zepbound are essentially the same drug with different labels and different insurance coverage pathways. This distinction matters more for your wallet than for your body.

How Much Weight Can You Lose on Zepbound, Mounjaro, or Ozempic?

Let me give you the clinical trial data, because that is the most reliable information we have.

Semaglutide (Ozempic/Wegovy)

The STEP 1 trial, published in the New England Journal of Medicine in 2021, showed that patients on semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks. For a 250-pound person, that translates to roughly 37 pounds.

Tirzepatide (Mounjaro/Zepbound)

The SURMOUNT-1 trial, also published in the New England Journal of Medicine in 2022, showed that patients on the highest dose of tirzepatide (15 mg) lost an average of 22.5% of their body weight over 72 weeks. For that same 250-pound person, that is about 56 pounds. Even the middle dose (10 mg) produced an average weight loss of 19.5%.

These are averages. Some patients lose more. Some lose less. Individual results depend on starting weight, diet changes, physical activity, genetics, and medication tolerance.

For comparison, bariatric surgery typically produces 25-35% excess weight loss in the first year for sleeve gastrectomy, and even more for gastric bypass. Surgery remains the most effective and durable treatment for severe obesity, but these medications have narrowed the gap significantly.

What Are the Side Effects?

The side effect profiles are similar across all three medications because they work through overlapping mechanisms. The most common issues are gastrointestinal.

Common Side Effects

• Nausea (the most frequent complaint, especially when starting or increasing the dose)
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Decreased appetite (which is partly the point, but it can be uncomfortable)

Most patients find that nausea improves after the first few weeks on a given dose. This is why all three medications use a gradual dose escalation schedule. You start low and increase over several months.

Serious But Less Common Risks

• Pancreatitis: Rare but documented. If you develop severe abdominal pain that radiates to your back, contact your doctor immediately.
• Gallbladder problems: Rapid weight loss from any cause increases gallstone risk. This applies to these medications just as it does to bariatric surgery or very low-calorie diets.
• Thyroid tumors: In animal studies, GLP-1 receptor agonists caused thyroid C-cell tumors in rodents. This has not been confirmed in humans, but these medications carry a boxed warning and should not be used by anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
• Gastroparesis: Some patients develop significant stomach-emptying delays. In my practice, I have seen cases where this persists even after stopping the medication, though this is uncommon.

In my experience with over 4,000 bariatric patients, I have noticed that people who have had prior stomach surgery sometimes tolerate these medications differently. If you have had a sleeve gastrectomy or gastric bypass, talk with your surgeon before starting any of these drugs.

How Much Do They Cost?

Let me be honest about this because cost is one of the biggest barriers my patients face.

Without insurance, all three medications cost roughly $1,000 to $1,300 per month. That is a significant expense, and it is ongoing because weight regain after stopping is common.

Insurance Coverage

• Ozempic: Often covered when prescribed for type 2 diabetes. Coverage for weight loss alone is inconsistent.
• Mounjaro: Covered by many plans for type 2 diabetes. Some plans now cover it for weight loss, but this varies widely.
• Zepbound: Because it is specifically approved for weight management, some insurers cover it for obesity without requiring a diabetes diagnosis. However, many plans still exclude weight loss medications entirely.

Manufacturer savings programs exist for all three, but eligibility requirements change frequently. Check directly with the manufacturer websites for current offers.

One thing I tell my patients: factor in the long-term cost. If you need to stay on these medications indefinitely to maintain weight loss (and current data suggests many people do), you are looking at a substantial ongoing expense. This is one reason I still believe bariatric surgery offers better long-term value for patients with severe obesity. Surgery is a one-time intervention with durable results.

Which One Should You Choose?

This depends on your specific medical situation.

If you have type 2 diabetes and want to lose weight: Mounjaro or Ozempic are both reasonable first choices. Your insurance coverage will likely determine which one is more accessible. Mounjaro has shown better blood sugar control and more weight loss in head-to-head comparisons with semaglutide for diabetes (the SURPASS trials).

If your primary goal is weight loss and you do not have diabetes: Zepbound is the tirzepatide option approved for this indication. Wegovy (semaglutide 2.4 mg) is the alternative. Again, insurance coverage and availability often drive the final decision.

If you have tried semaglutide and hit a plateau: Switching to tirzepatide is a reasonable strategy. The dual receptor mechanism means your body may respond differently. I have seen patients in my practice who stalled on Ozempic and then lost additional weight after switching to Mounjaro or Zepbound.

If cost is a primary concern: Be realistic about what you can sustain. Starting a medication you cannot afford long-term sets you up for weight regain when you stop.

What Happens When You Stop Taking Them?

This is the question I wish more patients asked before starting. A study published in the journal Diabetes, Obesity and Metabolism in 2022 followed patients who stopped tirzepatide after 36 weeks of treatment. Within a year of stopping, participants regained about two-thirds of the weight they had lost.

Similar patterns have been observed with semaglutide. The STEP 1 extension trial showed that one year after stopping semaglutide, patients regained roughly two-thirds of their lost weight.

This does not mean these medications are not worthwhile. It means you should plan for long-term use or combine them with other strategies. Some of my patients use these medications as a bridge to surgery or as an addition to their post-surgical plan. Others commit to indefinite medication use along with sustained lifestyle changes.

The key point: these medications treat obesity. They do not cure it. Just as you would not stop blood pressure medication and expect your blood pressure to stay normal, stopping weight loss medication usually leads to weight regain.

Can You Combine These Medications with Bariatric Surgery?

Yes, and this is an area where I think we will see a lot of development in coming years. Some patients benefit from using GLP-1 medications before surgery to reduce surgical risk by losing weight preoperatively. Others use them after surgery if they experience weight regain.

In my practice, I approach this individually. A patient who had a sleeve gastrectomy five years ago and has regained 30 pounds may benefit from adding a GLP-1 medication rather than undergoing revision surgery. On the other hand, a patient with a BMI of 50 who has never had surgery will likely get better long-term results from a surgical procedure than from medication alone.

This is not an either-or decision. Modern obesity treatment should use every effective tool we have.

Are These Medications Safe Long-Term?

We have about 5-6 years of data on semaglutide for weight loss and about 3-4 years for tirzepatide. That is a relatively short track record for medications intended for lifelong use. The SELECT trial did provide encouraging cardiovascular safety data for semaglutide, showing a 20% reduction in major cardiovascular events in patients with obesity and established heart disease.

Long-term tirzepatide cardiovascular outcomes data from the SURPASS-CVOT trial is still being collected.

From what we know so far, these medications appear safe for most patients. But “most patients” is not the same as “all patients.” Work with a physician who understands obesity medicine and can monitor you appropriately.

My Recommendation as a Bariatric Surgeon

After 20 years of treating obesity, I have seen the field transform. These medications are genuinely effective for many patients, and I prescribe them regularly in my practice. But I also see patients who have unrealistic expectations or who cannot sustain the cost.

Here is what I recommend:

1. Get a thorough evaluation from a physician experienced in obesity treatment. Your BMI, medical history, insurance coverage, and personal goals all factor into the right choice.
2. If your BMI is over 40, or over 35 with significant health problems, consider bariatric surgery alongside or instead of medication. The long-term data for surgery is far more robust.
3. If you start one of these medications, commit to the lifestyle changes that support it. Protein-focused nutrition, regular physical activity, and adequate sleep matter enormously.
4. Have a long-term plan. Ask yourself what happens at month 12 and month 24. Can you afford continued treatment? Are you prepared for what happens if you stop?

If you want to discuss whether Zepbound, Mounjaro, Ozempic, or surgery is the best fit for your situation, schedule a consultation. This decision deserves more than a 10-minute primary care visit.